-
More than 800,000 new crowns affect brain nerves in patients under 20 years old
Time of Update: 2021-12-01
According to a report from the European Network on the 22nd, the latest Italian research shows that the number of people under the age of 20 infected with the new crown has exceeded 800,000 .
-
The State Council's joint prevention and control: further prevention and control of the winter and spring epidemics
Time of Update: 2021-12-01
Wu Liangyou said that in accordance with the new crown virus vaccination arrangements in the second half of this year and the needs of winter epidemic prevention and control, we will continue to promote the vaccination of key populations and the new crown virus vaccination for people aged 3-11 .
-
The National Natural Science Foundation of China announces the list of the composition of the review team for the special project in the field of medical science
Time of Update: 2021-12-01
National Natural Science Fund Committee willCommittee member Department of Medical Sciences November 17, 2021
-
Health Commission: 24 newly diagnosed local cases on the 24th, 2 cases
Time of Update: 2021-12-01
As of 24:00 on November 24, according to reports from 31 provinces (autonomous regions and municipalities) and the Xinjiang Production and Construction Corps, there are currently 914 confirmed cases (including 8 severe cases), a total of 93,020 cured and discharged cases, and a total of 4,636 deaths.
-
A mechanism may affect the infectivity of new coronavirus mutant strains
Time of Update: 2021-12-01
Scientists at the National Institutes of Health found that mutations in Alpha and Delta mutant strains overcome the activity inhibitory effect of an enzyme called GALNT1, which may enhance the ability of the virus to enter cells and increase the ability of the virus to spread .
-
The National Pharmacopoeia Commission 2021 National Drug Standards to be Supplementary List Publicizes 9 types of excipients and 2 general technical methods for pharmaceutical packaging materials
Time of Update: 2021-12-01
Based on the deliberation of the preliminary application form, our committee has now determined the list of proposed supplementary topics for the improvement of national drug standards in 2021, which is now publicized, and the publicity period is 7 days .
-
Over 200,000 and 85% of Peruvian coronavirus deaths are obese
Time of Update: 2021-12-01
Dean In congressional health committee meeting will be on, the experts stressed, according to the National Death information systems, most of the new crown deaths are related to poor diet and cardiovascular issues, in addition to obesity, 43% had diabetes, 27% suffer from high Blood pressure .
-
A big test of Huiyu Pharmaceuticals: It was questioned all the way to officially land on the Sci-tech Innovation Board and enter the capital market
Time of Update: 2021-11-16
As the only generic drug manufacturer that passed the consistency evaluation at that time, Huiyu Pharmaceutical won the bid with a 65% price reduction to seize the market .
-
TOP10 failed clinical studies in September 2021
Time of Update: 2021-11-16
A head-to-head phase III study of Margetuximab in the treatment of breast cancerOn September 7, MacroGenics announced that the head-to-head SOPHIA study (NCT02492711) of Margetuximab versus trastuzumab combined with chemotherapy in the treatment of HER2-positive metastatic breast cancer did not prove to have a statistically significant advantage in the final OS analysis .
-
AbbVie's oral CGRP antagonist Qulipta receives FDA approval for preventive treatment of migraine
Time of Update: 2021-11-16
The results of the key phase 2b/3 trial of the drug showed that all three doses of Qulipta treatment group reached the primary efficacy endpoint of improvement from baseline in average migraine days during the 12-week treatment period, and the patient was compared with the baseline level of the placebo group.
-
Deck Pharmaceuticals announced that it will hold its first R&D day on November 16 and 18, 2021
Time of Update: 2021-11-16
November 16th: Online meeting (English session) November 18: Offline meeting will be webcast simultaneously (Chinese session)Shanghai and Hong Kong October 25, 2021/PRNewswire/ - A leading biopharmaceutical company dedicated to the research, development and commercialization of innovative tumor therapies – Deqi Pharmaceutical Co.
-
HRS9531 Injection, a subsidiary of Hengrui Pharmaceuticals, obtained the notification of drug clinical trial approval
Time of Update: 2021-11-16
HRS9531 injection is an innovative drug independently developed by the company, and its indication is type 2 diabetes .
-
Hengrui Cyclophosphamide Capsules intends to give priority to review while 2 new drugs are approved for clinical trials
Time of Update: 2021-11-16
Article source: Medical Rubik's Cube InfoAuthor: SunshineRecently, the CDE official website showed that Hengrui cyclophosphamide capsules are planned to be included in the priority review and are suitable for the treatment of lymphoma, leukemia, neuroblastoma, ovarian adenocarcinoma, retinoblastoma, breast cancer and many other tumor types .
-
Hongri Pharmaceutical Co., Ltd. obtains FDA approval for the treatment of sepsis with picrocramide B mesylate for injection
Time of Update: 2021-11-16
In February 2018, it obtained Phase II/III Clinical Approval (Lot No.
After obtaining the US FDA clinical trial qualification this time, KB's phase II clinical research plan for the treatment of patients with sepsis will be carried out in the United States .
-
The first drug to treat uveitis-related macular edema!
Time of Update: 2021-11-16
Xipere is designed to use the proprietary SCS Microinjector® technology developed by Clearside to treat macular edema associated with uveitis through suprachoroidal administration .
-
Next year, submit a new indication application for the blockbuster IL-4/IL-13 inhibitor phase 3 clinical report again
Time of Update: 2021-11-16
Today, Regeneron and Sanofi announced that Dupixent, a blockbuster IL-4/IL-13 inhibitor, reached the dual primary endpoint in the second clinical trial for the treatment of eosinophilic esophagitis (EoE) .
-
Many pharmacies who bought and sold pharmacist's certificates were chased for criminal responsibility
Time of Update: 2021-11-16
"According to the information in the indictment, since April 2020, the defendant Yang Moujia (manager of the store management department of a pharmaceutical chain company in Jiaxing City) has collected more than RMB 580,000 for the application of certificates from 68 personnel for the purpose of profit-making.
-
Why is the poisonous "Cruise officinalis" in Yang Guo's body really a medicine?
Time of Update: 2021-11-16
Figure 3 Alkaloids in GelsemiumPharmacological studies have proved that Gelsemium alkaloids have the effects of analgesia, immune regulation and tumor growth inhibition, and they are clinically used to treat cancer pain, sciatica, smooth muscle colic and other pains, as well as eczema, furuncle carbuncle, and psoriasis.
-
Many "problem" pharmacies in Beijing closed for rectification
Time of Update: 2021-11-16
Shijingshan night investigation and unannounced visit to closed problem pharmaciesThe Shijingshan District Market Supervision Bureau has also stepped up its inspections of pharmacies in its jurisdiction, and organized law enforcement personnel to conduct open and unannounced visits to the pharmacies' implementation of epidemic prevention and control through the linkage of science and research institutes .
-
Lybalvi launches in the U.S. to treat schizophrenia and bipolar I disorder
Time of Update: 2021-11-16
The approval is based on data from 27 clinical studies, including 18 studies evaluating Lybalvi, 9 studies evaluating samidorphan separately, and FDA's olanzapine treatment of biphasic An investigation into the safety and effectiveness of type I disorders and schizophrenia was found .
